Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Benzoxime carbaldehyde prevents rheumatoid arthritis in a rat model by inhibition of oxidative damage

Zhi-ming Li, Yanming Wang, Shujun Gai, Tao He

Department of Orthopaedic Surgery, Dezhou People's Hospital, Dezhou, Shandong, 253014, China;

For correspondence:- Tao He Email: TrulaVsch@yahoo.com Tel:+865342265514

Accepted: 21 July 2018 Published: 31 August 2018

Citation: Li Z, Wang Y, Gai S, He T. Benzoxime carbaldehyde prevents rheumatoid arthritis in a rat model by inhibition of oxidative damage. Trop J Pharm Res 2018; 17(8):1579-1584 doi: 10.4314/tjpr.v17i8.16

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of benzoxime carbaldehyde (BXCD) on rheumatoid arthritis (RA) in a rat model.

Methods: Thirty male Sprague-Dawley rats were assigned randomly to 5 groups (6 rats per group): normal control, RA, and three treatment groups. Rats in the normal control and RA groups received normal saline, whereas those in the three treatment groups were given 2, 5 or 10 mg/kg of BXCD daily for 30 days by intraperitoneal injection. Pressure pain was analysed using electronic pressure pain detector, while the expressions of interleukin (IL)-6, interleukin (IL)-1β, nuclear factor (NF)-κB p65 and tumor necrosis factor (TNF)-α in serum were determined using enzyme-linked immunosorbent assay (ELISA) kits.

Results: Treatment of RA rats with BXCD for 30 days led to significant (p < 0.05) recovery in pain threshold. At a dose of 10 mg/kg, BXCD decreased pain threshold value to a level comparable to that in normal control rats, and decreased arthritis score to 1, relative to arthritis score of 16 in untreated animals. Malondialdehyde (MDA) level was 4-fold higher in untreated RA rats than in normal and BXCD-treated groups. BXCD treatment increased the activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px), and blocked increases in the blood levels of IL-6, IL-1β, NF-κB p65 unit, and TNF-α. Western blot assay showed that BXCD treatment prevented increase in the level of cyclooxygenase-2 (COX-2) in RA rat tissues.

Conclusion: These results indicate that BXCD prevents RA in a rat model via inhibition of expressions of inflammatory cytokines and decrease in oxidative stress. Thus, BXCD has a strong potential for the management of RA

Keywords: Rheumatoid arthritis, Pain threshold, Antioxidant enzymes, Inflammation, Inflammatory cytokines